as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹116.93
Change
-1.17 (-0.99%)
Open
₹119.9
Prev. Close
₹118.1
Day High
₹120.46
Day Low
₹115.85
Volume Analysis
Traded
56,963
Delivered
28,907
Delivery %
50.75%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (3)
- •Low return on equity (0.41%)
- •Below-average fundamentals quality score (39/100)
- •Low operating margin (-13.0%)
Opportunities (0)
No signal for this stock
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹124.26 | ₹122.36 | ₹119.65 | ₹117.75 | ₹115.04 | ₹113.14 | ₹110.43 |
| Fibonacci | ₹122.36 | ₹120.6 | ₹119.51 | ₹117.75 | ₹115.99 | ₹114.9 | ₹113.14 |
| Camarilla | ₹118.2 | ₹117.78 | ₹117.35 | ₹117.75 | ₹116.51 | ₹116.08 | ₹115.66 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+17.13%
1 Week
-5.64%
1 Month
-6.81%
3 Months
+6.74%
6 Months
+57.63%
1 Year
-11.3%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹10.81
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
10.3%
Net margin 12.05% × asset turnover 0.57x × equity multiplier 1.5x
Company Overview
Sector
Healthcare
Market Cap
₹1,077 Cr
P/E (TTM)
624.0
ROE
0.41%
Book Value
₹43.3
Face Value
₹1.0
Source: Screener.in (Consolidated figures) — data as of 27 Sep 2026. Not investment advice.
TopFund Analysis
Themis Medicare Ltd. scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 39/100. The strongest factor is Financial Strength (100/100), while Cash Flow (0/100) is the weakest area to weigh before deciding. Notably: Low return on equity (0.41%); below-average fundamentals quality score (39/100).
TopFund Score — Fundamentals Quality
39/100 — WeakData confidence: 78/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has been maintaining a healthy dividend payout of 143%
- −Stock is trading at 2.70 times its book value
- −Company has low interest coverage ratio.
- −The company has delivered a poor sales growth of 8.21% over past five years.
- −Company has a low return on equity of 6.41% over last 3 years.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Themis Medicare withdrew proposed issue of 45,95,795 convertible warrants at Rs 102.87 each.
Record date set for final dividend FY2025-26 on September 23, 2026; AGM on September 30, 2026.
Please refer to Newspaper publication for Notice of 56th AGM scheduled on 30th September, 2026.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 97 | 105 | 83 | 98 | 123 | 117 | 94 | 72 | 98 | 78 | 90 | 77 | 87 |
| Expenses + | 75 | 92 | 74 | 89 | 94 | 100 | 88 | 79 | 108 | 81 | 80 | 73 | 139 |
| Operating Profit | 22 | 12 | 8 | 9 | 29 | 17 | 6 | -8 | -10 | -3 | 10 | 4 | -52 |
| OPM % | 22.0% | 12.0% | 10.0% | 10.0% | 24.0% | 15.0% | 6.0% | -11.0% | -10.0% | -4.0% | 11.0% | 4.9% | -60.0% |
| Other Income + | 6 | 7 | 6 | 5 | 7 | 6 | 1 | 2 | 1 | 5 | 6 | 11 | 97 |
| Interest | 2 | 2 | 3 | 2 | 2 | 2 | 3 | 2 | 2 | 3 | 3 | 3 | 3 |
| Depreciation | 3 | 3 | 3 | 3 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Profit before tax | 23 | 14 | 8 | 9 | 31 | 18 | 2 | -11 | -14 | -3 | 10 | 9 | 39 |
| Tax % | 19.0% | 19.0% | 10.0% | 24.0% | 21.0% | 20.0% | 69.0% | -13.0% | 1.0% | 5.0% | 3.0% | 2.0% | 36.0% |
| Net Profit + | 18 | 11 | 7 | 7 | 25 | 14 | 1 | -10 | -14 | -4 | 10 | 9 | 25 |
| EPS in Rs | 2 | 1 | 1 | 1 | 3 | 2 | 0 | -1 | -2 | 0 | 1 | 1 | 3 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 202 | 232 | 217 | 210 | 184 | 202 | 231 | 395 | 354 | 382 | 406 | 342 | 332 |
| Expenses + | 184 | 194 | 184 | 184 | 181 | 166 | 181 | 299 | 287 | 330 | 356 | 342 | 374 |
| Operating Profit | 18 | 38 | 33 | 25 | 2 | 36 | 49 | 96 | 67 | 52 | 49 | 0 | -42 |
| OPM % | 9.0% | 16.0% | 15.0% | 12.0% | 1.2% | 18.0% | 21.0% | 24.0% | 19.0% | 13.0% | 12.0% | 0.1% | -13.0% |
| Other Income + | 13 | 3 | 4 | 6 | 5 | 12 | 13 | 18 | 25 | 24 | 11 | 23 | 118 |
| Interest | 15 | 12 | 12 | 12 | 12 | 13 | 13 | 9 | 10 | 9 | 10 | 11 | 11 |
| Depreciation | 11 | 12 | 7 | 7 | 8 | 8 | 9 | 9 | 10 | 12 | 10 | 10 | 10 |
| Profit before tax | 5 | 17 | 18 | 11 | -13 | 27 | 41 | 95 | 73 | 53 | 40 | 2 | 55 |
| Tax % | -20.0% | 11.0% | 9.0% | 1.0% | -15.0% | 8.0% | 14.0% | 23.0% | 22.0% | 19.0% | 25.0% | 40.0% | — |
| Net Profit + | 6 | 16 | 16 | 11 | -11 | 25 | 36 | 73 | 57 | 44 | 30 | 1 | 40 |
| EPS in Rs | 1 | 2 | 2 | 1 | -1 | 3 | 4 | 8 | 6 | 5 | 3 | 0 | 4 |
| Dividend Payout % | 25.0% | 9.0% | 0.0% | 0.0% | 0.0% | 6.0% | 11.0% | 6.0% | 8.0% | 11.0% | 15.0% | 404.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 51 | 66 | 143 | 160 | 149 | 174 | 209 | 278 | 330 | 368 | 393 | 389 |
| Borrowings + | 140 | 128 | 82 | 80 | 82 | 100 | 87 | 80 | 92 | 96 | 83 | 100 |
| Other Liabilities + | 77 | 73 | 54 | 56 | 74 | 67 | 65 | 61 | 82 | 93 | 102 | 99 |
| Total Liabilities | 277 | 275 | 289 | 305 | 314 | 350 | 371 | 428 | 514 | 566 | 588 | 598 |
| Fixed Assets + | 122 | 117 | 124 | 126 | 123 | 116 | 133 | 144 | 162 | 168 | 172 | 167 |
| CWIP | 4 | 6 | 9 | 2 | 2 | 8 | 2 | 3 | 3 | 3 | 3 | 2 |
| Investments | 5 | 6 | 23 | 24 | 27 | 35 | 45 | 56 | 70 | 89 | 95 | 109 |
| Other Assets + | 146 | 146 | 133 | 153 | 162 | 191 | 191 | 225 | 279 | 307 | 318 | 320 |
| Total Assets | 277 | 275 | 289 | 305 | 314 | 350 | 371 | 428 | 514 | 566 | 588 | 598 |
| Equity Capital | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 19 | 26 | -2 | 8 | 11 | 0 | 57 | 34 | 16 | 22 | 35 | -3 |
| Cash from Investing Activity + | -6 | -7 | -4 | 0 | -4 | -5 | -16 | -16 | -24 | -16 | -12 | -3 |
| Cash from Financing Activity + | -18 | -13 | 5 | -9 | -10 | 7 | -26 | -18 | 0 | -9 | -26 | 4 |
| Net Cash Flow | -5 | 5 | 0 | -1 | -3 | 2 | 16 | 1 | -8 | -3 | -3 | -2 |
| CFO/OP | 101 | 73 | -5 | 29 | 490 | 2 | 115 | 55 | 48 | 60 | 93 | 782 |
| Free Cash Flow | 13 | 18 | -7 | 5 | 5 | -5 | 39 | 15 | -13 | 4 | 21 | -8 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 32.77% | 32.82% | 32.81% | 32.79% | 32.74% | 32.75% | 32.7% | 32.75% | 32.77% | 32.84% | 32.78% | 32.87% |
| Promoters | 67.16% | 67.16% | 67.15% | 67.15% | 67.15% | 67.15% | 67.15% | 67.15% | 67.15% | 67.1% | 67.1% | 67.1% |
| FII | 0.05% | 0.01% | 0.03% | 0.05% | 0.1% | 0.1% | 0.14% | 0.09% | 0.06% | 0.05% | 0.11% | 0.01% |
| DII | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Themis Medicare Ltd. (this stock) | 1,077 | 624.0 | 2.7 | 0.41% |
| Bharat Parenterals Ltd. | 1,077 | — | 3.3 | -2.54% |
| Laxmi Dental Limited | 1,097 | 31.6 | 4.49 | 14.8% |
| Sigachi Industries Ltd | 1,125 | 50.0 | 2.16 | 5.78% |
| Lincoln Pharma Ltd | 1,182 | 12.2 | 1.56 | 12.3% |
| 3b Blackbio Dx Ltd. | 1,207 | 21.7 | 3.72 | 19.8% |
| Shree Ganesh Remedies Ltd | 946 | 61.2 | 5.8 | 10.8% |
Which Mutual Funds Hold Themis Medicare Ltd.?
Frequently Asked Questions about Themis Medicare Ltd.
Themis Medicare Ltd. (THEMISMED) closed at ₹116.93 on NSE on 25 September 2026, down 1.17 (0.99%) from the previous close.
Themis Medicare Ltd. trades on the NSE (National Stock Exchange of India) under the symbol THEMISMED.
Themis Medicare Ltd. has a trailing twelve-month P/E (price-to-earnings) ratio of 624.0.
Themis Medicare Ltd. has a dividend yield of 0.43%.
Themis Medicare Ltd.'s 52-week high is ₹147.0 and its 52-week low is ₹65.0.
Themis Medicare Ltd. has a market capitalisation of ₹1,077 crore.
Themis Medicare Ltd. has a TopFund Quality Score of 39/100 (Weak), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Themis Medicare Ltd.?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.